134 related articles for article (PubMed ID: 38875031)
1. Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.
Chandler JM; Ye W; Mi X; Doty EG; Johnston JA
J Alzheimers Dis; 2024 Jun; ():. PubMed ID: 38875031
[TBL] [Abstract][Full Text] [Related]
2. Disease progression and costs at the 3-year follow-up of the GERAS-US study.
Chandler JM; Rentz DM; Zagar A; Kim Y; Schwartz RL; Fillit H
Alzheimers Dement (Amst); 2023; 15(2):e12430. PubMed ID: 37091310
[TBL] [Abstract][Full Text] [Related]
3. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
[TBL] [Abstract][Full Text] [Related]
4. Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes.
Jones RW; Lebrec J; Kahle-Wrobleski K; Dell'Agnello G; Bruno G; Vellas B; Argimon JM; Dodel R; Haro JM; Wimo A; Reed C
Dement Geriatr Cogn Dis Extra; 2017; 7(1):87-100. PubMed ID: 28611822
[TBL] [Abstract][Full Text] [Related]
5. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2018 Feb; 18(1):57. PubMed ID: 29471784
[TBL] [Abstract][Full Text] [Related]
6. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
[TBL] [Abstract][Full Text] [Related]
7. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
[TBL] [Abstract][Full Text] [Related]
8. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
[TBL] [Abstract][Full Text] [Related]
9. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
[TBL] [Abstract][Full Text] [Related]
10. Observation of Patient and Caregiver Burden Associated with Early Alzheimer's Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1.
Robinson RL; Rentz DM; Bruemmer V; Scott Andrews J; Zagar A; Kim Y; Schwartz RL; Ye W; Fillit HM
J Alzheimers Dis; 2019; 72(1):279-292. PubMed ID: 31561360
[TBL] [Abstract][Full Text] [Related]
11. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
[TBL] [Abstract][Full Text] [Related]
13. Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study.
Reed C; Belger M; Dell'Agnello G; Kahle-Wrobleski K; Sethuraman G; Hake A; Raskin J; Henley D
Alzheimers Res Ther; 2018 Apr; 10(1):36. PubMed ID: 29615123
[TBL] [Abstract][Full Text] [Related]
14. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
[TBL] [Abstract][Full Text] [Related]
15. Economic and caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study.
Dauphinot V; Potashman M; Levitchi-Benea M; Su R; Rubino I; Krolak-Salmon P
Alzheimers Res Ther; 2022 Feb; 14(1):34. PubMed ID: 35151368
[TBL] [Abstract][Full Text] [Related]
16. Potential Implications of Slowing Disease Progression in Amyloid-Positive Early Alzheimer's Disease: Estimates from Real-World Data.
Chandler J; Done N; Desai U; Georgieva M; Gomez-Lievano A; Ye W; Zhao A; Eid D; Hilts A; Kirson N; Schilling T
J Prev Alzheimers Dis; 2024; 11(2):310-319. PubMed ID: 38374737
[TBL] [Abstract][Full Text] [Related]
17. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
[TBL] [Abstract][Full Text] [Related]
18. Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.
Tahami Monfared AA; Khachatryan A; Hummel N; Kopiec A; Martinez M; Zhang R; Zhang Q
J Alzheimers Dis; 2024; 99(1):191-206. PubMed ID: 38640156
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
